When one patient is the whole trial
Approximately 7,000 rare diseases are known. Fewer than 5% have an approved treatment. Gene therapy has started to change that equation—not for thousands of patients at once, but for one child at a ti
The recent science is striking. A patient-specific adeno-associated virus (AAV) gene therapy for an ultra-rare neurological disease was designed and administered within 3 years of concept. A patient-specific base-editing therapy was created, cleared by regulators, and delivered to a newborn with a lethal metabolic disorder in under 8 months. In both cases, the biology worked. A child who had no options was treated.
Yet for every child who has received a therapy like this, many more have not. Companies that pioneered these one-time gene therapies have struggled commercially—some withdrawing products despite documented efficacy. The science is ready. The system for approving and delivering these therapies is not.
A paper published in Nature Medicine by Abou-el-Enein and colleagues at USC, UCSF, and UCLA describes a practical approach to fix this. Funded by the Advanced Research Projects Agency for Health (ARPA-H), the UNICORN system—Unifying Cell Therapy Outcome Prediction and Regulatory Navigation—is designed for exactly the situation where conventional drug development fails: when the trial has one patient, or three, or ten.
The core problem
Drug approval rests on three pillars: manufactured product quality, evidence of efficacy, and regulatory confidence. For large trials, these support each other naturally. Hundreds of patients generate statistical power. Manufacturing at scale smooths batch variability. Regulators see enough data to make confident decisions.
Rare and ultra-rare pediatric therapies break all three pillars at once. When a product is made in small batches—sometimes for a single child—donor variability and batch-to-batch differences directly affect quality, but there aren’t enough cases to characterize how. Clinical endpoints that work in large trials either don’t exist for rare diseases or don’t occur quickly enough to guide approval decisions. And regulators, charged with ensuring safety and efficacy, face an impossible ask: apply evidentiary thresholds built for populations of thousands to studies of one.
The result is a paradox. We can design a therapy for an individual child in months. We cannot reliably tell a regulator whether that therapy will work.
What UNICORN does, practically
The system has three connected parts.
Product signatures. A spectral flow cytometry panel developed at USC captures phenotypic, metabolic, and functional features of each cell therapy product. Instead of relying on a handful of traditional potency assays, this multi-parameter platform generates a high-dimensional product “signature”—a detailed fingerprint of each batch. The panel can be adapted to different products and run consistently across sites. This matters because it creates a common, comparable language for product quality across small-batch therapies that would otherwise be evaluated in isolation.
AI-driven outcome models. Machine learning models are trained on accumulated cases to identify correlations between product signatures and clinical outcomes. As more children are treated and more data are added, the models learn which product characteristics predict therapeutic benefit—and which predict risk. The point isn’t to replace human judgment. It’s to make the limited data that exists work harder. A model trained on 30 prior cases can say something meaningful about case 31. A regulator reviewing case 31 in isolation cannot.
Regulatory decision support. The third component translates model outputs into practical tools for regulatory conversations: lot-release criteria that define what a product must look like before it proceeds to clinical use, and evidence thresholds calibrated to what is realistically achievable when patient numbers are very small. The FDA has already signaled a willingness to adapt—its guidance on individualized antisense oligonucleotide therapies exemplifies this flexibility. UNICORN gives that flexibility an operational structure.
The system is designed to get stronger with use. Longitudinal sampling—repeated measurements before and after treatment, rather than single timepoints—multiplies the informational value of each case. Each new patient, product batch, and outcome dataset refines the models. What starts as a small evidence base grows into something that can meaningfully support the next approval decision.
Challenges and real limitations
The authors are direct about what this system cannot guarantee, and they deserve credit for it.
Biology won’t always conform to modeling assumptions. No single product signature is likely to fully predict outcomes across different diseases or treatment centers. Early datasets will be sparse and biased toward conditions already being treated—meaning less common ultra-rare diseases may be underrepresented until more cases accumulate. Unmeasured confounders and center-specific practices will influence both product signatures and patient outcomes in ways no model can fully account for. Some correlations that look predictive in retrospect may not hold going forward.
These are genuine constraints, not rhetorical caution. A system trained on small datasets is making probabilistic inferences under real uncertainty. The appropriate response is to build more rigorously and to be honest about what the current evidence can and cannot support.
Why this still represents real progress
The current alternative—applying population-trial standards to n-of-1 therapies—has already failed in practice. Products with documented clinical benefit have been pulled from the market. Children who could be treated are not. The status quo has its own costs, and they are measured in lives.
UNICORN’s value is not that it eliminates uncertainty. It is that it gives regulators, manufacturers, and clinicians a principled way to work with the uncertainty that exists, rather than demanding a level of certainty that can never arrive when the patient pool is a single child. A spectral flow cytometry signature contains more information than a traditional potency assay. A model trained on prior cases informs a release decision better than intuition alone. A decision-support tool that makes prior cases visible to the next regulator closes what is now a significant gap.
Each child treated under this system contributes to the evidence base for the next one. That is how rare disease knowledge accumulates when large randomized trials are not possible—incrementally, deliberately, with each case building on the last. The system is designed to learn. That is exactly what medicine needs when the study has one patient.
Source: Abou-el-Enein M et al. “A blueprint to accelerate rare pediatric gene therapy approvals.” Nature Medicine. 2025. doi:10.1038/s41591-025-04115-6. Funded by ARPA-H.